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Abstract
Hepatitis C virus (HCV) is a global health problem 
affecting a large fraction of the world’s population: This 
virus is able to determine both hepatic and extrahepatic 
diseases. Mixed cryoglobulinemia, a B-cell “benign” 
lymphoproliferative disorders, represents the most 
closely related as well as the most investigated HCV-
related extrahepatic disorder. Since this virus is able 
to determine extrahepatic [non-Hodgkin’s lymphoma 
(NHL)] as well as hepatic malignancies (hepatocellular 
carcinoma), HCV has been included among human 
cancer viruses. The most common histological types 
of HCV-associated NHL are the marginal zone, the 
lymphoplasmacytic and diffuse large cell lymphomas. 
The role of the HCV in the pathogenesis of the B-cell 
lymphoproliferative disorders is confirmed also by 
the responsiveness of the NHL to antiviral therapy. 
The purpose of this review is to provide an overview 
of the recent literature and a meta analysis of the 
epidemiology data, to explain the role of HCV in the 
development of NHL’s lymphoma. Furthermore, the 
possibility to treat these HCV-related NHL with the 
antiviral therapy or with other therapeutic options, like 
chemotherapy, is also discussed.  
Key words: Hepatitis C virus; Non-Hodgkin’s lymphoma; 
Hepatitis C virus genotypes; Alpha-interferon
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Hepatitis C virus and non-Hodgkin’s lymphomas: Meta-
analysis of epidemiology data and therapy options
an up-to-date meta-analysis of the risk to developing 
non-Hodgkin’s lymphomas in hepatitis C virus (HCV)-
infected patients. Finally, we highlighted the clinical 
and the biological data necessary to optimize the cure 
of the patients affected by HCV-positive non-Hodgkin’s 
lymphomas.
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INTRODUCTION
Non-Hodgkin’s lymphomas (NHL) are neoplastic diseases 
of the lymphoid tissue. Given the high heterogeneity 
in terms of histological and clinical characteristics, 
anatomical location, and putative aetiologies, several 
causative factors have been reported including inherited 
or acquired immunodeficiency, exposure to some toxic 
substances (pesticides) or radiation, smoking habits, 
and, in the last few years, infectious factors. In fact, the 
Epstein-Barr virus (EBV) has been shown to be involved 
in the development of the Burkitt’s lymphoma[1-3] and 
of other haematological malignancies (immunoblastic 
lymphoma, Hodgkin’s disease, nasopharyngeal car-
cinoma), the human retrovirus HTLV-I in the T-cell 
leukemia-lymphoma[4,5], and the double stranded DNA 
human herpes virus 8 in the Kaposi sarcoma[6,7], primary 
effusion lymphoma and multicentric Castleman disease[8]. 
But not only viruses are involved in pathogenesis of 
NHL, even the Gram-negative microaerophilic bacterium 
Helicobacter Pylori is thought to be the cause of gastric 
mucosa associated lymphoid (MALT) lymphoma[9,10]. 
However, although these infectious agents are wide-
spread (EBV infects near 100% of all populations and 
remains in B-cell throughout the life span), only a very 
small fraction of virus-carriers develops lymphomas. 
This indicates the key role of some, not yet understood, 
host factors: Maybe genetic factors like HLA antigens 
or cytokine signalling pathways or acquired factors 
like exposure to toxic substances (ethanol, drugs, 
etc.) or immunosuppression secondary to therapy for 
rheumatological disorders or to chemotherapy for mali-
gnancies.  
Hepatitis C virus (HCV) is a RNA virus belonging 
to the flaviviruses discovered in 1990 and involved in 
acute and chronic liver disease. The genome consists of 
a single-positive-stranded RNA molecule enveloped by 
a lipid bilayer within which two different glycoproteins 
are anchored[11]. The viral genome contains three 
distinct regions[12]: (1) a short 5′ non-coding region 
with two domains: A stem-loop structure involved in 
HCV replication and the internal ribosome entry site the 
structure responsible for attachment of the ribosome 
and polyprotein translation[13]; (2) A large, unique open 
reading frame of more than 9000 nucleotides, which 
encodes a single polyprotein precursor, that is cleaved 
co- and post-translationally to give the structural and 
non-structural viral proteins; and (3) The 3’ non-
translated region endowed with high variability in the 
length and structure. The HCV shows a high genetic 
diversity since, similarly to all RNA positive-strand 
viruses, the RNA-dependent RNA polymerase lacks a 
3’-5’ exonuclease proofreading activity for removal of the 
misincorporated bases. Therefore, the viral replication 
is error-prone, and this determines a large number 
of variants (quasispecies virus population)[14]. The 
frequency of the nucleotide mutations ranges from 1.4 
× 103 to 1.9 × 103 substitutions per nucleotide per year. 
The HCV is classified into six genotypes with a different 
distribution by geographical region and between patient 
groups; each genotype contains a variable number of 
genetically distinct “subtypes”. At the nucleotide level, 
the genotypes differ from each other by 31% to 33%, 
while subtypes from 20% to 25%[15]. The peculiar 
characteristic of HCV is the ability to infect not only the 
liver cells but also the lymphocytes[16] and, likely, other 
cells and tissues[17,18]. This is due on the fact that liver 
cells and lymphocytes share the same HCV receptor, 
i.e., the CD81. The lymphotropism might explain the 
several extra hepatic manifestations of the chronic HCV 
infection[19-26], among which mixed cryoglobulinemia 
(MC) is the most common[27-32]. MC is a disease 
characterised by the presence in the serum of immuno-
complexes able to precipitate with cold temperature 
and to re-dissolve with rewarming[33]. The main clinical 
manifestations of this disease are the skin lesions 
(purpura) secondary to vasculitis, which is caused by the 
deposition of the cryoglobulins in the small and medium 
sized blood vessels[34]. In addition to skin lesions, MC 
may involve several organs and tissues, determining 
peripheral neuropathy and/or glomerulonephritis. 
Since cryoglobulins are the production of monoclonal 
B-cells and lymphoid infiltrates are present frequently 
in the bone marrow[35] of these patients, MC should be 
considered as a smouldering lymphoma. Accordingly, 
even the first cases of MC described by Melzer, later, by 
other researchers[36-38] developed lymphomas months or 
years after the onset of the symptoms of MC[39]. These 
reports suggest that chronic HCV infection induces clonal 
B-cell proliferation, which can evolve from a “benign” 
lymphoproliferative disorder to an overt malignant 
lymphoma[40]. Since, according to some estimates, near 
170 million of people are carriers of the virus[41], the 
clinical impact of the extrahepatic disorders, leading to 
neoplastic diseases of the hemopoietic system in addition 
to the liver diseases, makes HCV a major public health 
problem. 
THE EPIDEMIOLOGY OF HCV-POSITIVE 
NHL: META-ANALYSIS UP-DATING
The first studies, which described the association of 
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HCV and lymphoproliferative disorders, were performed 
recording the prevalence of anti-HCV antibodies in 
small-unselected groups of patients affected by lym-
phomas[42-46]. These preliminary reports excluded 
the association between HCV infection and Hodgkin’s 
disease, while showed a strong association between NHL 
and HCV, especially in low-grade lymphomas. However, 
this association was found mainly in Italy and other 
researchers from the North of Europe did not confirm 
these findings. Therefore, some authors considered this 
relationship as due to the high prevalence of HCV in the 
Italian general population. In the following years, several 
studies addressed the possible association between 
HCV and NHL[47] and many papers have been published 
from different areas of the world. At present, more 
than 10000 cases of NHL have been screened for the 
presence of HCV infection and several meta-analyses on 
the relationship between HCV and lymphoma have been 
published[48,49]. 
In this review, the most recent meta-analysis have 
been updated to include only the studies (until the end 
of 2011) with a control groups. Unfortunately, these 
control groups were heterogeneous, in fact, some papers 
included patients with hematological diseases other than 
NHL, other studies included cases with solid cancers, or 
cases undergoing an invasive procedure (like surgery 
or endoscopy) or population-based samples, other 
studies enrolled volunteer blood donors. Only recently, 
some authors designed these studies as case-control 
or as cohort studies with well-defined inclusion criteria. 
Therefore, these authors are able to estimate the odds 
ratios or the relative risks (RRs) adjusted for age, sex, 
and other confounding factors. In the present review, we 
discarded the studies including the patients with other 
lymphoproliferative diseases as control group since also 
these diseases might be correlated with HCV. In addition, 
we considered eligible for meta-analysis only the studies 
with at least one of the following requirements: (1) Sex- 
and age-adjusted RRs; (2) Cases and controls matched 
by age and sex; and (3) A measure of age and of the 
male/female ratio in both cases and controls. 
If the authors did not provide RRs, we calculated 
the crude RRs (with 95%CIs) according to the Wald 
method, assuming the items 2 and 3 were available. In 
the analysis on NHL and HCV infection, we discarded 
the papers including less than 100 cases of NHL, while 
we included all the prospective studies (case-control 
or cohort studies) regardless of the number of NHL 
enrolled. Several problems of comparability were found 
in the retrieved studies since not all authors shared the 
definition of lymphoma. For instance, some authors 
included chronic lymphocytic leukemia (CLL) among NHL 
cases, whereas others did not. Since CLL patients show 
a prevalence of HCV infection lower than that observed 
in the general population, the inclusion or the exclusion 
of this very common lymphoproliferative disorder has a 
great impact on the epidemiological studies. In addition, 
the CLL cells and the small lymphocytic lymphoma (SLL) 
have the same immuno-phenotype[50,51], but SLL was 
included among NHL by all authors[51]. Most authors 
excluded the cases with human immunodeficiency virus 
(HIV) infection; therefore, we did not review the studies 
including HIV patients. To avoid bias, we discarded 
also the studies including only selected populations, 
non-representative of general population[52,53]. Another 
problem was the method of checking and confirming the 
HCV infection: In the first papers, most authors used 
only the enzyme-linked immunosorbent assay (ELISA) 
whereas, more recently, most authors used recombinant 
immunoblot assay (RIBA). To increase the complexity 
of the analysis, some authors enrolled only the patients 
with active HCV replication, i.e., with detectable levels 
of serum HCV-RNA. Since the first generation ELISAs 
showed low sensitivity and specificity, in this review 
we included only the studies employing second or third 
generation ELISAs. However, we did not consider the 
detection of HCV-RNA as a requirement for including a 
study. 
Statistical methods: We calculated the summary 
RR and corresponding 95%CI with the models of 
DerSimonian and Laird, which incorporate both within 
and between-study variability, as a weighted average 
of the estimated RRs, by giving each study a weight 
proportional to its precision. The heterogeneity among 
studies was evaluated using the Q statistics. The Begg’s 
and Egger’s asymmetry tests were used to assess the 
publication bias.
Figure 1 indicates the results of studies on HCV and 
NHL. The highest prevalence of HCV infection in the 
general population (over 20%) was found in Egypt. A 
rather high prevalence (5%-10%) was found in Italy 
and in Japan, while most countries (South Korea, 
Northern Europe, United States, Australia, and Canada) 
showed a prevalence below 5%. The 19 case-controls 
studies included in this review enrolled altogether 9038 
cases and 12224 controls. The pooled RR from this large 
group was 2.4 (95%CI: 2.0-3.0), and most of them 
(11/19) showed a RRs significantly elevated (Figure 
1). The RRs of the cohort studies was 2.0 (95%CI: 
1.4-3.0). The overall RR estimation was 2.3 (95%CI: 
1.8-2.9) with no significant heterogeneity between study 
designs. The different prevalence of the HCV infection in 
the control groups determined the great heterogeneity 
in the results. In fact, the studies performed in areas 
with a high HCV prevalence (above 5%) showed a 
more elevated RR (> 3) than those performed in areas 
with a low HCV prevalence (RR < 2). A significant 
heterogeneity emerged also for the publication period: 
In fact, the studies published up to 2003 indicated 
higher RRs when compared with the studies carried out 
thereafter. In addition, there are regional variations: 
people infected by HCV from Japan and from the 
Mediterranean basin show a relative risk of NHL from 2 
to 4 times higher than people of Northern Europe[54]. 
The mechanisms by which lymphoma is induced by 
HCV are still limited. The HCV-induced transformation 
process of B-cell may occur in three ways: (1) Chronic 
stimulation of B-Cell Receptor or other receptors placed 
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NHL.
In conclusions, HCV infection seems to be associated 
with a 2.5-fold increase in the risk of developing NHL. The 
fraction of the NHL secondary to HCV infection may be 
10%-15% in areas where HCV prevalence is high, but 
it is smaller in the countries of low prevalence. Based 
on epidemiological and experimental evidence, IARC 
recently concluded that there was sufficient evidence 
in humans to indicate the HCV infection as a cause of 
non-Hodgkin lymphomas, in addition to the previously 
recognized causal association with hepatocellular 
carcinoma[57].
THE THERAPY OF HCV-POSITIVE NHL
As previously indicated, the HCV-positive NHL are 
heterogeneous in terms of histological features and 
clinical aspects. The most common HCV-related 
NHL are indolent lymphomas (marginal-zone), but 
several aggressive and, rarely, very aggressive NHL 
are reported. Since the relationship between viral 
on the surface of B-cells by the viral antigens (in 
absence of cell infection) with secondary proliferation; (2) 
Infection and persistent replication of HCV inside B-cells 
with oncogenic effects by some viral proteins; and (3) 
Temporary intracellular virus replication with damage of 
B-cells[55]. However, since an active replication of HCV 
in human B or T lymphocytes in vivo (with evidence 
of the HCV-RNA negative strands) has never been 
demonstrated, a direct oncogenic effect by HCV inside 
B cells is unlikely. In addition, viral proteins, indicative 
of active replication, could never be demonstrated in 
the neoplastic lymphoid tissue of the HCV-NHL. Based 
on these considerations, it is likely that the neoplastic 
transformation is determined by the chronic antigen 
stimulation of B cells by viral surface proteins[56]. There 
are several experimental data supporting this theory: 
(1) the B lymphocytes from HCV patients show a higher 
level of activation markers[56] than normal lymphocyte; 
and (2) the long-term exposure to the epitopes of HCV 
lead to selection and expansion of a oligoclonal B-cells, 
which evolve in clonal B-cells and finally in an overt HCV-
Cases Controls RR 95%CI
HCV+/HCV- HCV+/HCV-
(Observed) (Expected)
Zuckerman, 1997 (United States) 29/94   6/108 4.98 1.96-12.65
Vallisa, 1999 (Italy)   65/110 32/318 5.87 3.65-9.44
Mizorogi, 2000 (Japan)   17/117 34/482 2.06 1.11-3.82
Pioltelli, 2000 (Italy)   48/252 66/781 2.25 1.51-3.35
Montella, 2001 (Italy) 28/83 17/209 3.70 1.90-7.20
Imai, 2002 (Japan)   23/164 (10) 2.39 1.41-4.05
Kim, 2002 (South Korea)    7/207 19/846 1.51 0.63-3.62
Mele/Bianco, 2003/2004 (Italy)   83/447 22/374 3.16 1.93-5.15
Cowgill, 2004 (Egypt)   94/126 52/170 2.70 1.80-4.05
Engels, 2004 (United States)   32/781 14/670 1.89 1.00-3.57
Iwata, 2004 (Japan)   15/117 29/539 2.38 1.24-4.57
Morton, 2004 (United States)     8/456   5/529 1.86 0.60-5.77
Sève, 2004 (France )     6/206 20/954 1.31 0.51-3.37
Talamini, 2004 (Italy)   44/181 45/459 2.64 1.62-4.30
Vajdic, 2006 (Australia)     3/594   2/520 1.32 0.22-7.92
Nieters, 2006 (Europe)     43/1304 41/1747 1.40 0.91-2.17
Sonmez, 2007 (Turkey)     3/106 28/523 0.53 0.13-2.16
Schollkopf, 2008 (Denmark Sweden)     20/2333    7/1849 2.20 0.90-5.38
Spinelli, 2008 (Canada)   19/776 5/692 2.57 0.89-7.42
All case-control studies   584/8454   454/11770 2.40 1.96-2.95
Test of heterogeneity between case-control studies: χ 2 (18df) = 33.65; P  = 0.014
Cohort studies
   Rabkin, 2001 (United States) 0/57 0/95 2.72 1.46-5.05
(Observed) (Expected) - -
   Oshawa, 1999 (Japan) (4)  (1.9) 2.10 0.57-7.74
   Duberg, 2005 (Sweden)   (24) (12) 1.98 1.27-3.09
   Ulcickas Yood, 2007 (United States) (3)  (0.8) 2.36 0.74-7.53
All cohort studies   (31)    (14.8) 2.03 1.37-3.02
Test of heterogeneity between cohort studies: χ 2 (2df) = 0.08; P  = 0.961
All 2.30 1.83-2.88
Test of heterogeneity by study design: χ 2 (1df) = 0.54; P  = 0.462
0.25              1       2       4         10
Relative risk
Figure 1  Relative risk estimates and corresponding 95%CI of non-Hodgkin’s lymphoma by hepatitis C virus seropositivity in case-control and cohort 
studies.
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replication and monoclonal lympho-proliferation is by 
now consolidated, the antiviral therapy could appear to 
be an attractive therapeutic option, in analogy to the 
antibiotic therapy employed to treat MALT lymphoma 
associated with Helicobacter Pylori infection[7]. However, 
before starting antiviral treatment of “bona fide” 
HCV-related NHL, several points should be taken in 
consideration, including: (1) Is the NHL really related 
with HCV infection? How the haematologist can be sure 
that a given NHL is HCV-associated? (2) Which is the 
best therapeutic approach? (3) Is the chemotherapy 
safe? In the case of the need to plan a chemotherapy, 
are the HCV-positive NHL exposed to higher risks than 
HCV-negative cases? and (4) The outcome of the HCV 
+ NHL is the same as compared with the HCV-NHL with 
the same histotype?
The HCV-related NHL show some typical, histological, 
clinical, laboratory and molecular characteristics. The 
most common histological types of HCV+NHL are 
lymphoplasmacytic, primary nodal marginal zone, 
splenic marginal zone, MALT marginal zone, while other 
histotypes are less closely associated with HCV[58-61]. 
The clinical course of the disease is generally indolent. 
The most common feature of true HCV + NHL is the 
longstanding presence of MC[62], and the late appearance 
of overt NHL, often after years from the onset of the 
clinical symptoms of MC. From a biological point of view, 
the HCV-related NHL often show a monoclonal IgMk 
component and the presence of several auto-antibodies 
(mainly anti-thyroid). From a molecular point of view, 
these patients use a restricted IgHV gene repertoire[63], 
with a strong bias for the IGHV1-69 and V3-A27[64,65]. In 
addition, the same set of V region genes, VH1-69 and 
Vk3 -A27 encode for the monoclonal IgMk component 
(if present). Finally the bcl-2/IgH translocation has been 
described in some studies, although not confirmed 
by others, present in HCV + NHL, at least of the 
lymphoplasmacytic subtype[66-68].
To choose the best therapeutic strategy several 
factors should be taken in consideration. Firstly the 
tumour burden: If there are large or huge nodal or extra 
nodal masses, chemotherapy becomes the first choice; 
on the contrary, if the tumour burden is low (confined to 
enlarged spleen and mild lymphoid infiltration of bone 
marrow) antiviral therapy is more indicated. A second 
factor to be considered is the course of the disease: If the 
course is indolent and lymphoma discovered occasionally 
during the follow-up of the patient, the antiviral therapy 
is more attractive, while if the patient show progressive 
and rapid node or spleen enlargement, chemotherapy 
is again the best choice. A third factor should be always 
taken in consideration, i.e., the presence or the absence 
of a chronic liver disease (CLD), and, if present, the 
severity of such a CLD. This means that the patient 
should undergo a complete hepatological evaluation 
including ultrasonography and, if indicated, endoscopy 
and liver biopsy. If the patient is affected by chronic 
C hepatitis without evidence of cirrhosis, the antiviral 
therapy should be indicated, while an advanced chronic 
liver disease with severe portal hypertension could be a 
contra-indication for antiviral and chemotherapy as well. 
A fourth factor to be considered is the presence and 
the quality of clinical symptoms. In fact the symptoms 
could be tumour-related (fever, weight loss, asthenia, 
etc.) or MC-related (vasculitis, neuropathy, arthralgias, 
etc.), in the former case chemotherapy is indicated 
while in the latter antiviral treatment could be the 
right choice. Finally, some specific contra-indications 
to antiviral therapy should be considered, often not 
familiar to haematologists[69], like deep depression[70,71] 
or immunological disorders[72]. 
The presence of HCV replication, i.e., detectable 
levels of HCV-RNA, without liver disease, cannot be 
considered a contra-indication for chemotherapy. In 
fact, the experience in the treatment of HCV + cryo-
globulinemia[73] shows that when these patients undergo 
either anti-CD20 therapy, or other intensive immuno-
suppressive treatment, tough a mild elevation of HCV-
RNA levels has been noticed, the liver function never 
worsens. On the contrary, some author reported a 
mild improvement in some cases. Despite few papers 
focused on this topic, the literature data confirm this 
point of view: Faggioli et al[74], in a small series of cases, 
did not detect any acute hepatitis due to the reactivation 
of HCV replication. These data were confirmed by other 
authors in larger cohorts of patients: Takai et al[75] found 
that, after chemotherapy, the fraction of NHL patients 
who developed liver function test alterations was higher 
in non-hepatitis virus carriers (12%) than in HCV-
bearing patients (10%), while a significant proportion 
of HBsAg carriers (36%) showed post-chemotherapy 
liver injuries. To further confirm these data, Visco et 
al[76], during the follow-up of 136 HCV-positive diffuse 
large cell lymphomas, found that only 5 cases (4%) 
discontinued the chemotherapy due to severe liver 
function impairment. It is noteworthy that 9 cases 
(7%) of the series had liver cirrhosis, and 26 cases had 
chronic hepatitis (19%). Altogether, this means that 
even in presence of HCV-related chronic liver disease, 
chemotherapy is feasible with a reasonable margin of 
safety. 
Contradictory data on the outcome of HCV-positive 
NHL are present is the literature. A first Japanese paper 
of Tomita et al[77] showed that the cases affected by 
HCV-positive aggressive NHL have the same prognosis 
as HCV-negative aggressive NHL, at least in the 
subjects without an advanced chronic liver disease. On 
the contrary, Besson et al[78], grouping together two 
large GELA studies (NHL93 and NHL98), found that the 
proportion of patients with high and high-intermediate 
IPI was higher among HCV-positive patients, and that, 
at 2 years, the OS and PFS of HCV-positive cases was 
56% vs 80% and 53% vs 75%,respectively. These 
surprising results could be explained, at least in part, by 
taking into account a possible selection bias of cases. 
In fact, the prevalence of HCV in these two cohorts of 
cases affected by NHL is largely lower (0.46%) of that 
found in the general population of France, where the 
Pozzato G et al . Hepatitis C virus and non-Hodgkin’s lymphomas
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prevalence is 2.8%. Since, as previously indicated, the 
prevalence of HCV-infection is always higher in NHL 
than in the general population[79], the very low number 
of HCV-positivity in the two groups of patients indicates 
the possibility of a selective enrolment in the trial of 
high-risk HCV-positive cases only, while standard- or 
low-risk cases were discarded. Nearly at the same time, 
Visco et al[76] following his large cohort of HCV-positive 
NHL showed that the OS and PFS of HCV-positive cases 
were similar to HCV-negatives. The question is still open 
and further controlled clinical trials should be needed to 
have definitive answers.
As shown in Table 1, antiviral therapy of HCV-NHL 
yielded different outcomes, according to the various 
authors. Since the number of cases is usually rather 
limited, several histotypes were enrolled with obvious 
different response rates, which makes published data 
are often contradictory. Moreover, several authors 
included cases with liver disease while others excluded 
these cases, and, finally, the presence of cryoglobu-
linemia is scattered among the cases and not recorded 
by all the authors. From 1996 to 2011, only 112 cases 
of HCV-positive NHL underwent antiviral therapy, the 
first three groups have been treated with interferon 
alone, thereafter with interferon and ribavirin and 
the last three groups with PEG-interferon (PEG-IFN) 
and ribavirin. The different antiviral power of these 
three regimens increases the difficult to interpret the 
results. In the first studies, the complete remission 
of the lymphomas was obtained in large fractions of 
patients (75% range: 64% to 84%), but most cases 
relapsed within few months. Much better results were 
achieved in the patients affected by splenic lymphoma 
with villous lymphocytes[80], in fact all HCV-positive 
cases entered complete remission upon treatment with 
interferon alone or with interferon and ribavirin, while 
HCV-negative lymphomas with villous lymphocytes 
controls did not benefit from antiviral therapy. The 
results obtained by Hermine et al[80] were confirmed 
subsequently by other studies[81-83]. These results 
suggest to perform a systematic screening for HCV in 
the patients affected by the marginal-zone lymphomas, 
since in the HCV-RNA positive cases, the antiviral 
therapy should be considered the treatment of choice. 
Several studies have documented the regression of 
different histotypes of NHL after antiviral treatment, 
such as lymphoplasmacytic lymphoma[84-86], mantle-
cell lymphoma[87], nodal marginal zone lymphomas[88] 
or extranodal marginal zone lymphoma of MALT tissue 
(MALT lymphomas)[89]. In the last three published 
studies all the patients were treated with the same 
antiviral regimen (PEG-IFN plus ribavirin), allowing better 
interpretation of the homogeneous results. In all three 
papers the haematological response significantly (P < 
0.005) correlates to the disappearance of HCV-RNA, and 
the sustained virological response was more frequently 
obtained in patients with genotype 2 or 3 more than 
genotype 1 or 4, which are usually found in HCV-chronic 
hepatitis without NHL. Given the high antiviral power of 
the treatment, the relapse rate is lower in these three 
studies (30%) than that previously recorded. At present, 
no data are available on the triple therapy in HCV-NHL. 
CONCLUSION
In addiction of acute and chronic liver diseases, the HCV 
infection determines many extra hepatic manifestations. 
Among them, the ability of the virus to interact with 
B cells leads to antigen-driven B-cell transformation, 
which ultimately may determine MC and finally a frank 
NHL. Based on clinical and biological considerations, the 
antiviral therapy should be considered as the treatment 
Table 1  Main studies of antiviral therapy in patients with hepatitis C virus infection and non-Hodgkin’s lymphoma (reports with 
single cases were discarded)
Ref. n Lymphoma histology (n) Disease sites
BM-S-LN-PB
MC type 
Ⅱ (n )
Antiviral therapy (n) SVR 
(n)
NHL response (n) Response 
duration (mo)
Mazzaro et al[94]   6 LPL (6) 6-0-2-0   4 IFN  (6)   4 CR (3) PR (1) 12 (8-18)
Moccia et al[95]   3 SMZL (3) 1-3-0-0 NR IFN (3)   2 CR (2) NR (1) 24 (5-40)
Hermine et al[80]   9 SLVL (9) 6-9-5-9   6 IFN (7) IFN-RBV (2)   7 CR (7) PR (1)   27 (15-40)
NR (1)
Arcaini et al[96]   4 SMZL (4) 4-4-1-2 NR IFN + RBV (4)   3 CR (2) PR (1) 36 (1-16)
Kelaidi et al[82]   8 SMZL (4) MZL/MALT (4) 7-6-2-6   8 IFN (2) IFN + RBV (6)   5 CR (5) PR (1)   6
Pitini et al[97]   2 SMZL (2) 2-2-1-2 NR IFN (2)   2 CR (2)   9
Saadoun et al[83] 18 SLVL (18) 10-18-8-10 18 IFN (8) IFN + RBV (10) 14 CR (14) PR (4) 62
Tursi et al[89] 16 MZL/MALT (16) NR NR IFN + RBV (16) 11 CR (11) NotR
Vallisa et al[86] 13 SMZL (4) MALT (4) FL (1) 
LPL (4)
5-4-0-6   5 PEG-IFN + RBV (13)   7 CR (7) PR (2) 14 (2-24)
Mazzaro et al[85] 18 SLVL (1), FL (1), LPL (16) 16-2-2-16 13 IFN + RBV (8)    3 CR (3) PR (2) 18 (8-32)
   PEG-IFN + RBV (10)   6 CR (6) PR (2)
Paulli et al[98]   2 MZL/MALT (2) Cutaneous   2 PEG-IFN + RBV   2 CR (1) PR (1) NotR
Pellicelli et al[88]   9 SMZL (3) MZL (4) FL (2) NR   4 PEG-IFN + RBV (9)   7 CR (5) PR (2) 12
MZL: Marginal zone lymphoma; SMZL: Splenic marginal zone lymphoma; SLVL: Splenic lymphoma with villous lymphocytes; FL: Follicular lymphoma; 
LPL: Lymphoplasmacytic lymphoma; BM: Bone marrow; S: Spleen; LN: Lymph nodes; PB: Peripheral blood; IFN: Alfa2a/Alfa2b interferon 3 times a week; 
RBV: Ribavirin; PEG-IFN: Pegylated alfa2a/alfa2b interferon; CR: Complete remission; PR: Partial remission; NR: No response; SVR: Sustained virological 
response; NotR: Not reported.
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of choice in HCV-associated lymphomas, especially in 
the presence of MC. However, the traditional antiviral 
therapy, based on PEG-IFN plus RIBA, is fading given the 
low efficacy and the numerous and severe side effects. 
At present, a new era is born for the management of 
HCV infection: The new strong direct antiviral agents[90-93]
opened the gate for a complete eradication of viral 
infection. These new drugs, described as lacking in 
side effects, can be used even in heavily pretreated 
patients or in cases with advanced liver disease with 
high possibility of success. It is likely that these new 
treatment options will be able to reduce drastically the 
number of the chronic carriers of HCV, as consequence, 
the number of HCV-related NHL.
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